जर्नल ऑफ़ डेवलपिंग ड्रग्स
खुला एक्सेस

अमूर्त

The Risk of Breast Carcinoma with Interferon Plus Ribavarin Therapy during Treatment of Chronic Hepatitis C Virus Infection-A Case Report

Manuela Stoicescu

The risk of therapy with interferon and Ribavarin has been reported, such as: dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms [1,2], but the risk of breast carcinoma of therapy with interferon and Ribavarin has not been seen.